gastrointestinal cancer: hepatocellular carcinoma (HCC)

Studies

ID Name Stage Status
1199.37 BIBF 1120 vs. Sorafenib for advanced hepatocellular carcinoma various active
  Registry of liver tumors various active
CP12-0919 Ramucirumab drug product + BSC vs. placebo + BSC as second-line treatment various active
CRAD001C24100 metastatic
 closed
A6181170 metastatic
 closed
12917 metastatic
 closed
12414 adjuvant
 closed
CA182-034 Brivanib + best supportive care vs. placebo (BRISK PS Study) metastatic 2nd line
 closed
CRAD001O2301 RAD001 vs. placebo (EVOLVE-1) various closed
A4061058 Axitinib (AG-013736) + BSC vs. placebo + BSC in hepatocellular carcinoma various closed
HGS1012-C1103 Mapatumumab + sorafenib in advanced HCC various closed